Structure and biological properties of lentztrehalose: a novel trehalose analog.
A new trehalose analog, lentztrehalose [4-O-(2,3-dihydroxy-3-methylbutyl)trehalose], was isolated from an actinomycete Lentzea sp. Lentztrehalose is only weakly hydrolyzed by the trehalose-hydrolyzing enzyme, trehalase, so can be regarded as an enzyme-stable analog of trehalose. Although lentztrehalose does not show apparent toxicity to mammalian cells and microbes, it has antitumor activity in mice bearing S-180 sarcoma and Ehrlich carcinoma cells. In ovariectomized mice, lentztrehalose displayed a bone reinforcement effect in the femur that was superior to trehalose and induced non-morbid suppression of weight gain comparable with trehalose. These results indicate that enzyme-stable analogs of trehalose, such as lentztrehalose, may be more beneficial for human health and thus have potential as substitutes for trehalose as a sweetener.
Institute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Shun-ichi
S
Wada
Institute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Shun-ichi
S
Ohba
Institute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Tetsuya
T
Someno
Institute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Masaki
M
Hatano
Institute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Akio
A
Nomoto
D039903:Actinobacteria / Q000254:growth & development / Q000378:metabolism* / Q000648:ultrastructure; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D055808:Drug Discovery; D005260:Female; D006801:Humans; D051379:Mice; D008813:Mice, Inbred ICR; D015394:Molecular Structure; D064306:Non-Nutritive Sweeteners / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D012510:Sarcoma 180 / Q000188:drug therapy* / Q000473:pathology; D013379:Substrate Specificity; D016019:Survival Analysis; D014198:Trehalase / Q000378:metabolism; D014199:Trehalose / Q000031:analogs & derivatives* / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use; D047368:Tumor Burden / Q000187:drug effects; D015430:Weight Gain / Q000187:drug effects
C000588806:4-O-(2,3-dihydroxy-3-methylbutyl)trehalose; D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D064306:Non-Nutritive Sweeteners; D014199:Trehalose; D014198:Trehalase